Glutathione transferase pi (GSTpi) expression in breast cancer: An immunohistochemical and molecular study

Acta Histochemica

Volumn 114, Issue 5, 2012, Pages 510-517

  Jardim, Bruna Victorasso ^a   Moschetta, Marina Gobbe ^b   Gelaleti, Gabriela Bottaro ^a   Leonel, Camila ^a   Regiani, Vitor Rafael ^b   de Santi Neto, Dalisio ^b   Bordin Junior, Newton A ^b   Perea, Silvia Aparecida ^b   Zuccari, Debora Ap Pires de Campos ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

Breast cancer; Glutathione S transferase; Immunohistochemistry; Prognosis; Real time PCR

Indexed keywords

GLUTATHIONE TRANSFERASE P1; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION; GLUTATHIONE TRANSFERASE P1 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 84860368227     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.09.005     Document Type: Article

References (39)

1. Arai T., Miyoshi Y., Kim S.J., Akazawa K., Maruyama N., Taguchi T., et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008, 34:734-738.
2. Arun B.K., Granville L.A., Yin G., Middleton L.P., Dawood S., Kau S.W., et al. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest 2010, 28:554-559.
3. Buser K., Joncourt F., Altermatt H.J., Bacchi M., Oberli A., Cerny T. Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol 1997, 8:314-315.
4. Cairns J., Wright C., Cattan A.R., Hall A.G., Cantwell B.J., Harris A.L., et al. Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J Pathol 1992, 166:19-25.
5. Chekhun V.F., Zhylchuk V.E., Lukyanova N.Y., Vorontsova A.L., Kudryavets Y.I. Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients. Exp Oncol 2009, 31:123-124.
6. Duffy M.J., Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008, 54:1770-1779.
7. Duffy M.J., O'Donovan N., Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011, 37:151-159. 10.1016/j.ctrv.2010.07.004.
8. El-Rayes B.F, Ali S., Heilbrun L.K., Lababidi S., Bouwman D., Visscher D., et al. Cytochrome P450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 2003, 9:1705-1709.
9. Frierson H.F., Gaffey M.J., Meredith S.D., Boyd J.C., Williams M.E. Immunohistochemical staining and Southern blot hybridization for glutathione S-transferase pi in mammary infiltrating ductal carcinoma. Mod Pathol 1995, 8:643-647.
10. Gralow J., Ozols R.F., Bajorin D.F., Cheson B.D., Sandler H.M., Winer E.P., et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2008, 26:313-325.
11. Gonzalez-ângulo A.M., Moraes-Vasquez F., Hortobagyl G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
12. Haas S., Pierl C., Harth V., Pesch B., Rabstein S., Brüning T., et al. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer 2006, 119:1785-1791.
13. Hammond M.E., Hayes D.F., Wolff A.C., Mangu P.B., Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol Pract 2010, 6:195-197.
14. Hicks D.G., Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 2008, 132:1008-1015.
15. Huang J., Tan P.H., Thiyagarajan J., Bay B.H. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 2003, 16:558-565.
16. Huber P.C., Almeida W.P., Fatima A. Glutationa e enzimas relacionadas: papel biológico e importância em processos patológicos. Quím Nova 2008, 31:1170-1179.
17. Instituto Nacional do Câncer, (INCA) Estimativas da incidência e mortalidade por câncer no Brasil 2010, Ministério da Saúde, Rio de Janeiro, http://www.inca.gov.br/estimativa/2010/index.asp?link=conteudo_view.asp&ID=5 [accessed 20.11.10].
18. Kalinina E.V., Chernov N.N., Saprin A.N., Kotova Y.N., Remizov V.I., Shcherbak N.P. Expression of genes for redox-dependent glutathione S-transferase isoforms GSTP1-1 and GSTA4-4 in tumor cell during the development doxorubicin resistance. Bull Exp Biol Med 2007, 143:328-330.
19. Kumaraguruparan R., Balachandran C., Manohar B.M., Nagini S. Altered oxidant-antioxidant profile in canine mammary tumours. Vet Res Commun 2005, 29:287-296.
20. Lasabova Z., Tilandyova P., Kajo K., Zubor P., Burjanivova T., Danko J., et al. Hypermethylation of the GSTP1 promoter region in breast cancer is associated with prognostic clinicopathological parameters. Neoplasma 2010, 57:35-40.
21. Lapensee E.W., Schwemberger S.J., LaPensee C.R., Bahassi el M., Afton S.E., Ben-Jonathan N. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 2009, 30:1298-1304.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001, 25:402-408.
23. Malamou-Mitsi V., Gogas H., Dafni U., Bourli A., Fillipidis T., Sotiropoulou M., et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 2006, 17:1504-1511.
24. Martinez V., Kennedy S., Doolan P., Gammell P., Joyce H., Kenny E., et al. Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Res Treat 2008, 110:521-530.
25. Molina R., Oesterreich S., Zhou J.L., Tandon A.K., Clark G.M., Allred D.C., et al. Glutathione transferase GST pi in breast tumors evaluated by three techniques. Dis Markers 1993, 11:71-82.
26. Morais L.M., Cardoso Filho C., Lourenço G.J., Shinzato J.Y., Zeferino L.C., Lima C.S., et al. Características mamográficas do câncer de mama associadas aos polimorfismos GSTM1 e GSTT1. Rev Assoc Med Bras 2008, 54:61-66.
27. Murawaki Y., Tsuchiya H., Kanbe T., Harada K., Yashima K., Nozaka K., et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 2008, 259:218-230.
28. Pastore A., Federici G., Bertini E., Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 2003, 333:19-39.
29. Pedersen L., Gunnarsdottir K.A., Rasmussen B.B., Moeller S., Lanng C. The prognostic influence of multifocality in breast cancer patients. Breast 2004, 13:188-193.
30. Rajneesh C.P., Manimaran A., Sasikala K.R., Adaikappan P. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J 2008, 49:640-643.
31. Schmidt M., Bachhuber A., Victor A. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003, 129:295-302.
32. Silvestrini R., Veneroni S., Benini E., Daidone M.G., Luisi A., Leutner M., et al. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997, 89:639-645.
33. Soubeyran I., Quénel N., Mauriac L., Durand M., Bonichon F., Coindre J.-M. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer 1996, 73:735-743.
34. Su F., Hu X., Jia W., Gong C., Song E., Hamar P. Glutathione S-transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 2003, 113:102-108.
35. Thomas E., Berner G. Prognostic and predictive implications of HER2 Status for breast cancer patients. Eur J Oncol Nurs 2000, 4:10-17.
36. Townsend D.M., Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375.
37. Van't Veer L.J., Paik S., Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005, 23:1631-1635.
38. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
39. Vibet S., Goupille C., Bougnoux P., Steghens J.P., Goré J., Mahéo K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 2008, 7:1483-1491.